In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Coherus Oncology Inc (NASDAQ: CHRS) was $1.31 for the day, up 2.34% from the previous closing price of $1.28. In other words, the price has increased by $2.34 from its previous closing price. On the day, 0.97 million shares were traded. CHRS stock price reached its highest trading level at $1.3191 during the session, while it also had its lowest trading level at $1.25.
Ratios:
Our analysis of CHRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.23 and its Current Ratio is at 1.24. In the meantime, Its Debt-to-Equity ratio is 0.62 whereas as Long-Term Debt/Eq ratio is at 0.60.
On August 16, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $4 to $1.50.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.Robert W. Baird initiated its Outperform rating on November 17, 2023, with a $11 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 158341024 and an Enterprise Value of 20998028. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.89 while its Price-to-Book (P/B) ratio in mrq is 1.73. Its current Enterprise Value per Revenue stands at 0.076 whereas that against EBITDA is -0.263.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.98, which has changed by 0.07377052 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is -14.81%, while the 200-Day Moving Average is calculated to be 18.60%.
Shares Statistics:
CHRS traded an average of 1.24M shares per day over the past three months and 1183930 shares per day over the past ten days. A total of 116.24M shares are outstanding, with a floating share count of 102.19M. Insiders hold about 15.46% of the company’s shares, while institutions hold 41.98% stake in the company. Shares short for CHRS as of 1763078400 were 29176605 with a Short Ratio of 23.53, compared to 1760486400 on 30165888. Therefore, it implies a Short% of Shares Outstanding of 29176605 and a Short% of Float of 25.059998.
Earnings Estimates
The market rating for Coherus Oncology Inc (CHRS) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.27 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$1.33 and -$1.33 for the fiscal current year, implying an average EPS of -$1.33. EPS for the following year is -$0.49, with 1.0 analysts recommending between -$0.49 and -$0.49.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $17.57M to a low estimate of $13M. As of. The current estimate, Coherus Oncology Inc’s year-ago sales were $54.14MFor the next quarter, 4 analysts are estimating revenue of $17.96M. There is a high estimate of $20.61M for the next quarter, whereas the lowest estimate is $15.3M.
A total of 4 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $46.99M, while the lowest revenue estimate was $42.23M, resulting in an average revenue estimate of $43.82M. In the same quarter a year ago, actual revenue was $266.96MBased on 4 analysts’ estimates, the company’s revenue will be $94.63M in the next fiscal year. The high estimate is $155.29M and the low estimate is $62.42M.
